News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

As if Amarin Corporation PLC (AMRN) Needs Another Worry, Here Comes a Vascepa FDA Panel


6/7/2013 8:08:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Amarin (AMRN_) President John Thero made news -- and not necessarily the good kind -- at an investor conference Thursday when he said the company was preparing for a Vascepa FDA advisory panel later this year. A date for the FDA advisory panel has not been set, but Thero said the panel would review Amarin's prescription-grade fish oil pill for the so-called "Anchor" indication of treating patients with mixed dyslipidemia.

Help employers find you! Check out all the jobs and post your resume.

Read at The Street.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES